Benzinga | Jun 4, 2021 06:14AM EDT

HC Wainwright & Co. Initiates Coverage On Protara Therapeutics with Buy Rating, Announces Price Target of $40

HC Wainwright & Co. analyst Andrew Fein initiates coverage on Protara Therapeutics (NASDAQ:TARA) with a Buy rating and announces Price Target of $40.